Evidence map›Paper›PMID 28947474›Full record

ArticleAntimicrobial agents and chemotherapy2017

Pharmacokinetics-Pharmacodynamics of CB-618 in Combination with Cefepime, Ceftazidime, Ceftolozane, or Meropenem: the Pharmacological Basis for a Stand-Alone β-Lactamase Inhibitor.

Paul G Ambrose, Brian D VanScoy, Michael Trang, Jennifer McCauley-Miller, Haley Conde, Sujata M Bhavnani, Dylan C Alexander, Lawrence V Friedrich

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Paul G AmbroseInstitute for Clinical Pharmacodynamics, Schenectady, New York, USA PAmbrose@ICPD.com.
Brian D VanScoyInstitute for Clinical Pharmacodynamics, Schenectady, New York, USA.
Michael TrangInstitute for Clinical Pharmacodynamics, Schenectady, New York, USA.
Jennifer McCauley-MillerInstitute for Clinical Pharmacodynamics, Schenectady, New York, USA.
Haley CondeInstitute for Clinical Pharmacodynamics, Schenectady, New York, USA.
Sujata M BhavnaniInstitute for Clinical Pharmacodynamics, Schenectady, New York, USA.
Dylan C AlexanderMerck and Co., Kenilworth, New Jersey, USA.
Lawrence V FriedrichMerck and Co., Kenilworth, New Jersey, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A major challenge in treating patients is the selection of the "right" antibiotic regimen. Given that the optimal β-lactam/β-lactamase inhibitor pair is dependent upon the spectrum of β-lactamase enzymes produced and the frequency of resistance to the β-lactamase inhibitor, it might be useful if a stand-alone were available for the clinician to pair with the "right" β-lactam rather than only in a fixed combination. We describe herein a one-compartment

Indexed as

Anti-Bacterial Agentsbeta-Lactamase Inhibitorsbeta-LactamasesCefepimeCeftazidimeCephalosporinsComputer SimulationEnterobacter cloacaeEscherichia coliHumansKlebsiella pneumoniaeMeropenemMicrobial Sensitivity TestsThienamycinsAnti-Bacterial Agentsbeta-Lactamase Inhibitorsbeta-LactamasesCefepimeCeftazidimeceftolozaneCephalosporinsMeropenemThienamycinsCB-618pharmacokinetics-pharmacodynamicsβ-lactamase inhibitor

Identifiers

PMID28947474
PMCPMC5700306

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.